As cases of norovirus rise in Canada and the U.S., researchers show progress toward a vaccine. Moderna, an American pharmaceutical company, is developing an mRNA-based vaccine called mRNA-1403 to combat multiple norovirus strains. The company aims to use this technology to create a safe and effective immune response without causing infection. Stéphane Bancel, Moderna’s CEO, emphasized the importance of this advancement in addressing a significant public health issue that affects millions globally.
The surge of norovirus cases has been particularly notable in Canada, with recent data showing infections exceeding five-year averages. Last month, PHAC reported higher-than-average cases nationwide, including a cluster at the University of Guelph involving 190 individuals with gastroenteritis symptoms. Norovirus is highly contagious, causing symptoms like diarrhea and vomiting, often leading to severe complications such as dehydration.
With no approved vaccines or antivirals currently available for norovirus, Moderna’s efforts are crucial in filling this gap. The company’s Phase 3 trial, the Nova 301 Trial, seeks to validate its vaccine’s safety, effectiveness, and immune response among 25,000 participants globally. If successful, Moderna aims to submit a marketing application to U.S. health regulators by 2026.
Meanwhile, other companies like Vaxtart are exploring alternative approaches, including oral vaccines for potential efficiency. The race to develop effective treatments for norovirus underscores its significant impact on public health worldwide.
Source: https://globalnews.ca/news/10976310/norovirus-vaccine-modern-mrna-clinical-trials